Supplementary Figure from Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Qing Zhou(BGI Group (China)), Ellen Heitzer(Medical University of Graz), Angelika Pichler, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Anders Ståhlberg(Lund University), Martin Filipits(University of Vienna), Simon Peter Gampenrieder(University of Salzburg), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Rupert Bartsch(Universitätszahnklinik Wien), Daniel Egle(Innsbruck Medical University), Ricarda Graf, Margaretha Rudas(Comprehensive Cancer Center Vienna), Sophie Frantal(Statistics Austria), Sabrina Weber, Peter Dubsky(Hirslanden Klinik St. Anna), Gabriel Rinnerthaler(Medical University of Graz), Georg Pfeiler(Medical University of Vienna), Marija Balić(University of Pittsburgh), Nadia Dandachi(Medical University of Graz), Edgar Petru(Medical University of Graz), Christian F. Singer(Comprehensive Cancer Center Vienna), Viktor Wette, Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 0
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k